You are here

EpiPen fallout builds as adviser backs dumping Mylan board

Since acquiring the drug in 2007, Mylan has raised the price several times, to more than US$600 for a two-pack from about US$57 a shot.


MYLAN faces an increasing backlash over its handling of the EpiPen pricing controversy, as a top proxy adviser urged shareholders to oust the drugmaker's board.

Institutional Shareholder Services (ISS) said that the company's directors had failed to stop "significant...